Tsuchimoto Kim R
SEC CIK 1333516 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| MNPR | Monopar Therapeutics | Dir | 4,090 | — | $1.27M | 33 | 2021-06-30 | 2026-08-26 |
Most active insiders at MNPR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Tsuchimoto Kim R | Dir | — | $911.1K |
| 2 | Anderson Raymond | Dir | — | $703.0K |
| 3 | KLAUSNER ARTHUR J | Dir | — | $343.9K |
| 4 | Vu Quan Anh | CFO | $104.9K | — |
| 5 | RIOUX PATRICE | Acting Chief Medical Off | — | $111.26 |
| 6 | Cittadine Andrew | COO | — | — |
| 7 | Hendricks Diane | 10% | — | — |
| 8 | Robinson Chandler | CEO, Dir | — | — |
Transactions 33
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMAT | 2026-08-28 20:18 | 2026-08-26 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | Dir | M - OptEx | $22.04 | +4,090 | 4,090 | New | +$90.1K |
| DMAT | 2026-08-28 20:18 | 2026-08-26 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | Dir | S - Sale+OE | $111.39 | -4,090 | 0 | -100% | -$455.6K |
| MT | 2026-08-27 18:28 | 2026-08-26 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | Dir | S - Sale | $111.39 | -4,090 | 7,396 | -36% | -$455.6K |
| D | 2025-07-16 | 2025-07-14 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | Dir | X - OptEx | $0.01 | +8,904 | 20.4K | +78% | +$89.04 |
| D | 2025-07-16 | 2025-07-14 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | Dir | S - Sale+OE | $40.00 | -8,904 | 11.5K | -44% | -$356.2K |
| D | 2024-07-02 | 2024-06-30 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO, Dir | F - Tax | $0.73 | -2,998 | 57.4K | -5% | -$2,189 |
| D | 2024-07-02 | 2024-06-30 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO, Dir | M - OptEx | — | +9,957 | 60.4K | +20% | — |
| D | 2024-04-02 | 2024-03-31 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO, Dir | M - OptEx | — | +9,956 | 54.6K | +22% | — |
| D | 2024-04-02 | 2024-03-31 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO, Dir | F - Tax | $0.68 | -4,082 | 50.5K | -7% | -$2,776 |
| DM | 2024-01-03 | 2023-12-31+ | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO, Dir | M - OptEx | — | +11.2K | 45.1K | +33% | — |
| DM | 2024-01-03 | 2023-12-31+ | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO, Dir | F - Tax | $0.34 | -4,578 | 43.9K | -9% | -$1,557 |
| D | 2023-10-03 | 2023-09-30 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO, Dir | F - Tax | $0.62 | -3,444 | 38.0K | -8% | -$2,135 |
| D | 2023-10-03 | 2023-09-30 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO, Dir | M - OptEx | — | +9,956 | 41.4K | +32% | — |
| D | 2023-07-03 | 2023-06-30 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO, Dir | M - OptEx | — | +14.8K | 36.6K | +68% | — |
| D | 2023-07-03 | 2023-06-30 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO, Dir | F - Tax | $0.86 | -5,104 | 31.5K | -14% | -$4,389 |
| D | 2023-04-04 | 2023-03-31 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO, Dir | F - Tax | $1.39 | -1,842 | 21.7K | -8% | -$2,560 |
| D | 2023-04-04 | 2023-03-31 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO, Dir | M - OptEx | — | +5,067 | 23.6K | +27% | — |
| DM | 2023-01-03 | 2022-12-31+ | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO | F - Tax | $2.37 | -2,569 | 17.8K | -13% | -$6,089 |
| DM | 2023-01-03 | 2022-12-31+ | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO | M - OptEx | — | +6,297 | 19.8K | +46% | — |
| D | 2022-10-03 | 2022-09-30 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO | M - OptEx | — | +5,066 | 16.5K | +44% | — |
| D | 2022-10-03 | 2022-09-30 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO | F - Tax | $1.52 | -1,753 | 14.8K | -11% | -$2,665 |
| D | 2022-07-01 | 2022-06-30 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO | M - OptEx | — | +8,913 | 14.5K | +158% | — |
| D | 2022-07-01 | 2022-06-30 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO | F - Tax | $2.30 | -3,083 | 11.5K | -21% | -$7,091 |
| D | 2022-04-01 | 2022-03-31 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO | M - OptEx | — | +1,221 | 6,136 | +25% | — |
| D | 2022-04-01 | 2022-03-31 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO | F - Tax | $2.55 | -500 | 5,636 | -8% | -$1,275 |
| D | 2022-01-04 | 2021-12-31 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO | F - Tax | $3.21 | -501 | 4,189 | -11% | -$1,608 |
| D | 2022-01-04 | 2021-12-31 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO | M - OptEx | — | +1,221 | 4,690 | +35% | — |
| D | 2022-01-04 | 2022-01-01 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO | M - OptEx | — | +1,231 | 5,420 | +29% | — |
| D | 2022-01-04 | 2022-01-01 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO | F - Tax | $3.21 | -505 | 4,915 | -9% | -$1,621 |
| D | 2021-10-01 | 2021-09-30 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO | M - OptEx | — | +1,221 | 3,892 | +46% | — |
| D | 2021-10-01 | 2021-09-30 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO | F - Tax | $4.87 | -423 | 3,469 | -11% | -$2,060 |
| D | 2021-07-02 | 2021-06-30 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO | F - Tax | $5.89 | -823 | 2,671 | -24% | -$4,847 |
| D | 2021-07-02 | 2021-06-30 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | CFO | M - OptEx | — | +2,442 | 3,494 | +232% | — |
Purchase Sale Sale after option exercise All abbreviations